Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
10% cholesterol cream is a topical therapeutic formulation developed by the Institute of Dermatology, Thailand, for the treatment of autosomal recessive congenital ichthyosis (ARCI). ARCI is a rare genetic skin disorder characterized by a defective skin barrier due to impaired production or organization of natural lipids, such as cholesterol, ceramides, and fatty acids. This deficiency leads to increased transepidermal water loss (TEWL), resulting in severe dryness, scaling, and pruritus. Cholesterol is a critical physiological component of the stratum corneum's lamellar lipid matrix. By applying cholesterol topically at a high concentration, the treatment aims to replenish the lipid structure, restore barrier function, and improve skin hydration and patient quality of life.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on cholesterol cream.